Published in Exp Dermatol on August 01, 2010
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res (2011) 1.06
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer (2014) 0.88
SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. J Invest Dermatol (2013) 0.82
Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78
Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization. Mol Vis (2011) 0.77
Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells. Oncoimmunology (2016) 0.76
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen (2004) 2.94
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol (2013) 2.31
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Foreign body granulomas caused by polymethylmethacrylate microspheres: successful treatment with allopurinol. Arch Dermatol (2003) 2.23
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol (2009) 2.06
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet (2012) 2.03
Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol (2010) 2.03
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol (2007) 2.02
Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol (2008) 2.02
In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. Virchows Arch (2015) 1.98
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
Treatment of oral lichen planus with the 308-nm UVB excimer laser--early preliminary results in eight patients. Lasers Surg Med (2003) 1.79
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
Efficient transfection method for primary cells. Tissue Eng (2002) 1.74
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Tattoo pigments are cleaved by laser light-the chemical analysis in vitro provide evidence for hazardous compounds. Photochem Photobiol (2004) 1.66
Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol (2008) 1.65
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res (2005) 1.63
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62
Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res (2004) 1.61
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol (2005) 1.60
KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol (2011) 1.59
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59
Tattooing of skin results in transportation and light-induced decomposition of tattoo pigments--a first quantification in vivo using a mouse model. Exp Dermatol (2009) 1.55
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol (2005) 1.53
Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. J Invest Dermatol (2011) 1.51
Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res (2005) 1.49
Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells. Int J Mol Med (2011) 1.49
Seborrheic keratosis. J Dtsch Dermatol Ges (2008) 1.49
Weight gain in cachectic COPD patients receiving noninvasive positive-pressure ventilation. Respir Care (2006) 1.43
Granulomatous jellyfish dermatitis. J Dtsch Dermatol Ges (2007) 1.43
Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. Oncogene (2005) 1.41
Recent advances in betalain research. Phytochemistry (2003) 1.41
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res (2008) 1.40
Dysplastic melanocytic nevi of the lower leg: sex- and site-specific histopathology. Am J Dermatopathol (2010) 1.40
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet (2012) 1.40
Intense pulsed light (IPL): a review. Lasers Surg Med (2010) 1.39
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
[Smoking -- effects on the skin]. J Dtsch Dermatol Ges (2003) 1.38
Dead Sea treatment - principle for outpatient use in atopic dermatitis: safety and efficacy of synchronous balneophototherapy using narrowband UVB and bathing in Dead Sea salt solution. Eur J Dermatol (2002) 1.37
Gene expression profiling of melanocytes following Q-Switched Ruby laser irradiation. Dermatology (2008) 1.37
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
Computational pathology analysis of tissue microarrays predicts survival of renal clear cell carcinoma patients. Med Image Comput Comput Assist Interv (2008) 1.35
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer (2008) 1.34
HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33
Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res (2007) 1.33
Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells in vitro. Am J Physiol Cell Physiol (2006) 1.31
Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol (2010) 1.31
Different types of microsatellite instability in ovarian carcinoma. Int J Cancer (2004) 1.30
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis (2006) 1.29
The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma. Int J Cancer (2010) 1.29
Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control (2010) 1.28
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol (2004) 1.26
Occurence and clinical predictors of spasticity after ischemic stroke. Stroke (2010) 1.24
Singlet oxygen generation by UVA light exposure of endogenous photosensitizers. Biophys J (2006) 1.24
Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res (2002) 1.24
Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol (2009) 1.23
RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer (2008) 1.22
Relationship between tobacco control policies and the delivery of smoking cessation services in nonprofit HMOs. J Natl Cancer Inst Monogr (2005) 1.22
Plasma medicine: possible applications in dermatology. J Dtsch Dermatol Ges (2010) 1.21
Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer (2010) 1.21
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol (2006) 1.20